All lobbying filings

Plasma Protein Therapeutics Association

Plasma Protein Therapeutics Association filed a Q3 report for Plasma Protein Therapeutics Association on October 19, 2026.

Lobbying for Plasma Protein Therapeutics Association

As filed: PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION.

All filings by Plasma Protein Therapeutics Association · Everything Plasma Protein Therapeutics Association has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Expenses

$160,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. Pricing proposals such as reference pricing/Most Favored Nations as they relate to access to plasma derived therapies.

Health Issues

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and Alpha 1. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Trade (domestic/foreign)

Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.